Alpesh Amin
Hospitalist · Orange, CANPI 1457394801
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. Reporting peaked in 2019 at $125,848 and has fallen 84.4% since, to $19,615 in 2025. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 407 payments — averaging $1051.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$115K
- Gilead$98K
- Pfizer$85K
- Bayer$28K
- Novo Nordisk$16K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$14K
- plus $72K from 23 others
Across 48 payments — averaging $10,446 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$120K
- PTC Therapeutics, Inc.$100K
- Octapharma USA, Inc.$73K
- Diasorin Molecular LLC$42K
- Heron Therapeutics, Inc.$38K
- Amgen$37K
- plus $92K from 4 others
What the payments were for
- Consulting fees$194,80946%
- Speaking & faculty fees$145,21834%
- Grants$5,0751%
- Travel & lodging$73,16017%
- Food & beverage$8,4772%
- Education$1,2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 132 | $115,300 |
| Gilead | 115 | $98,328 |
| Pfizer(2 entities) | 44 | $84,760 |
| Bayer | 35 | $28,294 |
| Novo Nordisk | 11 | $15,849 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $13,863 |
| Novartis | 11 | $13,772 |
| Mylan Specialty L.p. | 14 | $11,550 |
| Ferring Pharmaceuticals Inc. | 9 | $8,965 |
| Boehringer Ingelheim | 1 | $7,968 |
| Paratek Pharmaceuticals, Inc. | 5 | $6,409 |
| E.r. Squibb & Sons, L.L.C. | 1 | $3,800 |
| Lilly USA, LLC | 1 | $3,600 |
| Amgen | 3 | $3,427 |
| Sanofi | 1 | $2,625 |
| Shionogi Inc | 1 | $2,080 |
| Invivyd Inc | 3 | $1,832 |
| Astrazeneca UK Limited | 1 | $1,800 |
| Dexcom, Inc. | 1 | $975 |
| AbbVie | 1 | $825 |
| Mylan Inc. | 2 | $824 |
| Novo Nordisk AS | 1 | $563 |
| Baxter Healthcare | 1 | $285 |
| Fisher & Paykel Healthcare Inc | 1 | $63 |
| Aimmune Therapeutics, Inc. | 1 | $56 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| CSL Behring | 1 | $40 |
| Beckman Coulter, Inc. | 1 | $26 |
| Hill-rom Company, Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$427,939 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $52,472 |
| EntrestoSacubitril/Valsartan | 39 | $27,823 |
| JardianceEmpagliflozin | 25 | $25,833 |
| MounjaroTirzepatide | 19 | $19,209 |
| WegovySemaglutide | 11 | $15,805 |
| RybelsusSemaglutide | 16 | $14,067 |
| Enoxaparin Sodium | 53 | $9,319 |
| Warfarin Sodium | 468 | $4,790 |
| Metoprolol Succinate | 23 | $482 |
| Losartan Potassium | 27 | $150 |
| Metformin Hcl | 13 | $98 |
| Amlodipine Besylate | 17 | $80 |
| Atorvastatin Calcium | 11 | $77 |
| Spironolactone | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $15,849 | $82,34376 claims |
| NovartisEntresto | $13,772 | $27,82339 claims |
| Boehringer IngelheimJardiance | $7,968 | $25,83325 claims |
| Lilly USA, LLCMounjaro | $3,600 | $19,20919 claims |
| Mylan Inc.Atorvastatin Calcium | $824 | $7711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.
Other hospitalist in Orange
- Anjani KolahiOrange$30K
- Omar DarwishOrange$22K
- Thomas KimOrange$5K
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
- Steven WongTorrance$36K
- Edward LeeLos Angeles$30K
- Omar AldaasSan Diego$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.